Current status of pulmonary arterial hypertension in Korea

키워드

참고문헌 (80)

1. Galie N, "2015 ESC", ERS guidelines for the diagnosis and treatment of pulmonary hypertension : the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS) : Endorsed by : Association for European Paediatric and Congenital Cardiology(AEPC), International Society for Heart and Lung Transplantation(ISHLT), 2016, pp.37, 67~119
2. National Pulmonary Hypertension Centres of the UK and Ireland, "Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland", Thorax, 63, pp.ii1~ii41 (2008)
3. Maron BA, "Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era : a review", JAMA Cardiol, 1, pp.1056~1065 (2016)
4. Fukuda K, "Guidelines for the treatment of pulmonary hypertension(JCS 2017", JPCPHS 2017), 2019, pp.83, 842~945
5. Galie N, "An overview of the 6th World Symposium on Pulmonary Hypertension", Eur Respir J, 53 (2019)
6. Klinger JR, "Therapy for pulmonary arterial hypertension in adults : update of the CHEST guideline and expert panel report", Chest, 155, pp.565~586 (2019)
7. Ogawa A, "Survival of Japanese patients with idiopathic", heritable pulmonary arterial hypertension, 2017, pp.119, 1479~1484
8. Zhang R, "Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era", Chest, 140, pp.301~309 (2011)
9. 정욱진, "Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension", Journal of Korean Medical Science, 30(10), pp.1429~1438 (2015), 대한의학회
10. Lim Y, "Pulmonary arterial hypertension in a multi-ethnic Asian population : characteristics, survival and mortality predictors from a 14-year follow-up study", Respirology, 24, pp.162~170 (2019)
11. Frost AE, "The changing picture of patients with pulmonary arterial hypertension in the United States : how REVEAL differs from historic and non-US Contemporary Registries", Chest, 139, pp.128~137 (2011)
12. Humbert M, "Pulmonary arterial hypertension in France : results from a national registry", Am J Respir Crit Care Med, 173, pp.1023~1030 (2006)
13. Escribano-Subias P, "Survival in pulmonary hypertension in Spain : insights from the Spanish registry", Eur Respir J, 40, pp.596~603 (2012)
14. Fernandes CJ, "Quality of life as a prognostic marker in pulmonary arterial hypertension", Health Qual Life Outcomes, 12, pp.130~ (2014)
15. Strange G, "Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension : the delay study", Pulm Circ, 3, pp.89~94 (2013)
16. 안지환, "Clinical Characteristics and Survival of Korean Idiopathic Pulmonary Arterial Hypertension Patients Based on Vasoreactivity", Journal of Korean Medical Science, 29(12), pp.1665~1671 (2014), 대한의학회
17. Kang BJ, "Improved survival of Korean patients with idiopathic pulmonary arterial hypertension after the introduction of targeted therapies", Heart Lung, 43, pp.561~568 (2014)
18. 박예민, "Functional Class and Targeted Therapy Are Related to the Survival in Patients with Pulmonary Arterial Hypertension", Yonsei Medical Journal, 55(6), pp.1526~1532 (2014), 연세대학교의과대학[DOI]
19. McGoon MD, "Pulmonary arterial hypertension : epidemiology and registries", J Am Coll Cardiol, 62, pp.D51~D59 (2013)
20. Chung L, "Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL : identifying systemic sclerosis as a unique phenotype", Chest, 138, pp.1383~1394 (2010)
21. Yang X, "Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases : a systematic review of the literature", Clin Rheumatol, 32, pp.1519~1531 (2013)
22. Song S, "Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea : a nationwide study based on the health insurance review and assessment service database", PLoS One, 13, pp.e0209148~ (2018)
23. Benza RL, "The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension", Chest, 141, pp.354~362 (2012)
24. Ogawa A, "Long-term patient survival with idiopathic", heritable pulmonary arterial hypertension treated at a single center in Japan, 2014, pp.118, 414~419
25. Loyd JE, "Familial primary pulmonary hypertension : clinical patterns", Am Rev Respir Dis, 129, pp.194~197 (1984)
26. Deng Z, "Familial primary pulmonary hypertension(gene PPH1)is caused by mutations in the bone morphogenetic protein receptor-II gene", Am J Hum Genet, 67, pp.737~744 (2000)
27. International PPH Consortium, "Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension", Nat Genet, 26, pp.81~84 (2000)
28. Evans JD, "BMPR2 mutations and survival in pulmonary arterial hypertension : an individual participant data meta-analysis", Lancet Respir Med, 4, pp.129~137 (2016)
29. Morrell NW, "Genetics and genomics of pulmonary arterial hypertension", Eur Respir J, 53 (2019)
30. "Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension (PILGRIM)" (2019)[URL]
31. Sztrymf B, "Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2mutation", Am J Respir Crit Care Med, 177, pp.1377~1383 (2008)
32. Liu D, "BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension", Circ Cardiovasc Genet, 5, pp.511~518 (2012)
33. Morisaki H, "BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension", Hum Mutat, 23, pp.632~ (2004)
34. Austin ED, "Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension", Respir Res, 10, pp.87~ (2009)
35. Pfarr N, "Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations", Respir Res, 12, pp.99~ (2011)
36. Kabata H, "Bone morphogenetic protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension", Respirology, 18, pp.1076~1082 (2013)
37. Pulido T, "Macitentan and morbidity and mortality in pulmonary arterial hypertension", N Engl J Med, 369, pp.809~818 (2013)
38. Ghofrani HA, "Riociguat for the treatment of pulmonary arterial hypertension", N Engl J Med, 369, pp.330~340 (2013)
39. Sitbon O, "Selexipag for the treatment of pulmonary arterial hypertension", N Engl J Med, 373, pp.2522~2533 (2015)
40. Galie N, "Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension", N Engl J Med, 373, pp.834~844 (2015)
41. McLaughlin VV, "Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension", Am J Respir Crit Care Med, 174, pp.1257~1263 (2006)
42. Simonneau G, "Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension : a randomized trial", Ann Intern Med, 149, pp.521~530 (2008)
43. Tapson VF, "Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and", or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial, 2012, pp.142, 1383~1390
44. Galie N, "Tadalafil therapy for pulmonary arterial hypertension", Circulation, 119, pp.2894~2903 (2009)
45. Iversen K, "Combination therapy with bosentan and sildenafil in Eisenmenger syndrome : a randomized, placebo-controlled, double-blinded trial", Eur Heart J, 31, pp.1124~1131 (2010)
46. Simonneau G, "Selexipag : an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension", Eur Respir J, 40, pp.874~880 (2012)
47. McLaughlin VV, "Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension : a randomized controlled clinical trial", J Am Coll Cardiol, 55, pp.1915~1922 (2010)
48. Galie N, "Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan(EARLY study) : a double-blind, randomised controlled trial", Lancet, 371, pp.2093~2100 (2008)
49. Sitbon O, "Upfront triple combination therapy in pulmonary arterial hypertension : a pilot study", Eur Respir J, 43, pp.1691~1697 (2014)
50. Hassoun PM, "Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension", Am J Respir Crit Care Med, 192, pp.1102~1110 (2015)
51. Tamura Y, "Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension", Circ J, 82, pp.275~282 (2017)
52. Akagi S, "Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension", J Cardiol, 72, pp.466~472 (2018)
53. Tokunaga N, "Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension", J Cardiol, 68, pp.542~547 (2016)
54. 안경진, "15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation", Clinical Hypertension, 25(4), pp.52~55 (2019), 대한고혈압학회[DOI]
55. Gaine S, "Pulmonary arterial hypertension:tailoring treatment to risk in the current era", Eur Respir Rev, 26 (2017)
56. Buda ES, "Lifestyle modification practice and associated factors among diagnosed hypertensive patients in selected hospitals, South Ethiopia", Clin Hypertens, 23, pp.26~ (2017)
57. Lee HT, "The relationship between visit-to-visit variability in blood pressure and incidence of metabolic syndrome : a general population-based cohort study in Korea", Clin Hypertens, 25, pp.11~ (2019)
58. Sa’adeh HH, "Knowledge, attitudes and practices of hypertensive patients towards prevention and early detection of chronic kidney disease : a cross sectional study from Palestine", Clin Hypertens, 24, pp.6~ (2018)
59. Tocci G, "Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice : results of the Italian hypertension and brain survey", Clin Hypertens, 23, pp.10~ (2017)
60. Mereles D, "Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension", Circulation, 114, pp.1482~1489 (2006)
61. Ruiter G, "Iron deficiency is common in idiopathic pulmonary arterial hypertension", Eur Respir J, 37, pp.1386~1391 (2011)
62. Howard LS, "Supplementation of iron in pulmonary hypertension : rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension", Pulm Circ, 3, pp.100~107 (2013)
63. Mirdamadi A, "Benefits from the correction of vitamin D deficiency in patients with pulmonary hypertension", Caspian J Intern Med, 7, pp.253~259 (2016)
64. Brown LM, "Delay in recognition of pulmonary arterial hypertension : factors identified from the REVEAL registry", Chest, 140, pp.19~26 (2011)
65. Austin ED, "Pulmonary hypertension: NHLBI Workshop on the primary prevention of chronic lung diseases", Ann Am Thorac Soc, 11, pp.S178~S185 (2014)
66. McLaughlin VV, "Contemporary trends in the diagnosis and management of pulmonary arterial hypertension : an initiative to close the care gap", Chest, 143, pp.324~332 (2013)
67. Lau EM, "Early detection of pulmonary vascular disease in pulmonary arterial hypertension : time to move forward", Eur Heart J, 32, pp.2489~2498 (2011)
68. Frost A, "Diagnosis of pulmonary hypertension", Eur Respir J, 53 (2019)
69. Hoeper MM, "Elderly patients diagnosed with idiopathic pulmonary arterial hypertension : results from the COMPERA registry", Int J Cardiol, 168, pp.871~880 (2013)
70. McGoon MD, "REVEAL : a contemporary US pulmonary arterial hypertension registry", Eur Respir Rev, 21, pp.8~18 (2012)
71. Jing ZC, "Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension", Chest, 132, pp.373~379 (2007)
72. Lau EMT, "Epidemiology and treatment of pulmonary arterial hypertension", Nat Rev Cardiol, 14, pp.603~614 (2017)
73. Humbert M, "Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era", Circulation, 122, pp.156~163 (2010)
74. Ling Y, "Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension : results from the pulmonary hypertension registry of the United Kingdom and Ireland", Am J Respir Crit Care Med, 186, pp.790~796 (2012)
75. Delude CM, "Deep phenotyping : the details of disease", Nature, 527, pp.S14~S15 (2015)
76. Purkait P, "Association of angiotensinogen gene SNPs and haplotypes with risk of hypertension in eastern Indian population", Clin Hypertens, 23, pp.12~ (2017)
77. Soubrier F, "Genetics and genomics of pulmonary arterial hypertension", J Am Coll Cardiol, 62, pp.D13~D21 (2013)
78. "Home" (2019)[URL]
79. "Home" (2019)[URL]
80. 장영우, "A Nationwide multicenter registry and biobank program for deep phenotyping of idiopathic and hereditary pulmonary arterial hypertension in Korea: the PAH platform for deep phenotyping in Korean subjects (PHOENIKS) cohort", Clinical Hypertension, 25(4), pp.39~44 (2019), 대한고혈압학회[DOI]

관련 논문AI추천